Once the intestinal lining is compromised, ammonia and various pro-inflammatory microbial products "leak" out and travel directly to the liver via the portal vein. This influx of foreign and toxic material acts as a call to arms for the liver’s immune system. One of the primary responses involves the over-activation of CD8+ T cells. While these immune cells are essential for destroying infected or cancerous cells, their hyper-activity in the liver creates a state of chronic inflammation that drives the progression of MASH.
"We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression," said Dr. Chen. "This compound shows benefits to the gastrointestinal system and has great potential as a treatment for MASH."
Experimental Drug Repairs the Gut and Protects the Liver
The researchers conducted a series of rigorous experiments to see if DT-109 could interrupt this cycle. Testing the compound in both mice and nonhuman primates, the team observed a consistent and powerful therapeutic effect.
In the treated subjects, DT-109 successfully reduced the populations of Clostridium perfringens. By lowering the abundance of these bacteria, the drug effectively reduced the production of ammonia in the gut. With the chemical assault on the intestinal lining halted, the gut barrier was able to repair itself and regain its integrity.
This restoration of the "gatekeeper" function had an immediate impact on liver health. Because the systemic translocation of toxins was curtailed, the inflammatory signals in the liver subsided. The results in nonhuman primates were particularly significant for the research team. Because primates share a much more similar liver biology and gut microbiome to humans than rodents do, the success in these models suggests a higher likelihood that the results could eventually be replicated in human patients.
In these primate models, the researchers documented a visible reduction in liver inflammation and a decrease in the overall severity of MASH. The study effectively proved that by stabilizing the gut-liver axis, the liver could be allowed to heal.
"DT-109 connects microbiota modulation with liver protection by restoring gut barrier integrity and limiting the systemic translocation of ammonia and other pro-inflammatory microbial products within the gut-liver axis," explained Jifeng Zhang, Ph.D., co-author of the study and a research professor of cardiovascular medicine at U-M Medical School. "We also found that DT-109 primarily acts in the gastrointestinal tract, but its reach stretches much further."
Potential Benefits Beyond Fatty Liver Disease
The implications of this research extend far beyond MASH. Because the gut-liver axis is a central component of overall metabolic health, a drug that can strengthen the intestinal barrier may have applications for a variety of other chronic conditions.
Metabolic disorders rarely affect just one organ in isolation. Patients with fatty liver disease are at a significantly higher risk for cardiovascular disease, which remains the leading cause of death for individuals with MASH. Previous research into DT-109 has already shown that the compound can reduce the formation of atherosclerotic plaques—the fatty deposits that clog arteries—and prevent vascular calcification in nonhuman primates. Vascular calcification, the buildup of calcium in the walls of blood vessels, makes arteries stiff and less responsive, a major factor in heart attacks and strokes.
